• Linc’s third-quarter 2026 earnings per share fell 72% year over year to 1.7 kronor.
• For the first nine months of 2026, earnings per share swung to a profit of 3.1 kronor.
• Net asset value rose year over year to 4.59 billion kronor at September 30, 2026.
• Portfolio company Egetis Therapeutics secured FDA approval for EMCITATE to treat adults and children with MCT8 deficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Linc AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.